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rameters for galectin-3 decreased in advanced pT and 
pN stages at a statistically signifi cant level. The number 
of positive cases was considerably smaller among the 
cases with small cell lung cancer than in the group with 
non-small-cell lung cancer, among which adenocarcino-
mas fi gured prominently with the exception of galec-
tin-1 expression. Kaplan-Meier computations revealed 
that the survival rate of patients with galectin-3-binding 
or galectin-1-expressing tumors was signifi cantly poorer 
than that of the negative cases. In the multivariate calcu-
lations of survival lymph node metastases (p  ! 0.0001), 
histological type (p = 0.003), galectin-3-binding capacity 
(p = 0.01), galectin-3 expression (p = 0.03) and pT status 
(p = 0.003) proved to be independent prognostic factors, 
not correlated with the pN stage.  Conclusion: The ex-
pression and the capacity to bind the adhesion/growth 
regulatory galectin-3 is defi ned as an unfavorable prog-
nostic factor not correlated with the pTN stage. 
 Copyright © 2005 S. Karger AG, Basel 
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 Abstract 
 Objective: To determine the expression of endogenous 
adhesion/growth-regulatory lectins and their binding 
sites using labeled tissue lectins as well as the binding 
profi le of hyaluronic acid as an approach to defi ne new 
prognostic markers.  Methods: Sections of paraffi n-em-
bedded histological material of 481 lungs from lung tu-
mor patients following radical lung excision processed 
by a routine immunohistochemical method (avidin-bio-
tin labeling, DAB chromogen). Specifi c antibodies 
against galectins-1 and -3 and the heparin-binding lectin 
were tested. Staining by labeled galectins and hyaluron-
ic acid was similarly visualized by a routine protocol. 
After semiquantitative assessment of staining, the re-
sults were compared with the pT and pN stages and the 
histological type. Survival was calculated by univariate 
and multivariate methods.  Results: Binding of galectin-1 
and its expression tended to increase, whereas the pa-
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 Introduction 
 Clinical procedures such as prognostic evaluations can 
benefi t from new insights into the biochemistry of tumor 
growth and spread. By defi ning relevant mechanisms at 
the molecular level it becomes feasible to test the predic-
tive values of newly defi ned markers in ensuing histo-
pathological studies. Our study is based on the current 
paradigmatic shift in the way the presence of cell surface 
carbohydrates and their changes in malignancy are being 
interpreted  [1, 2] . Initially, they were viewed as primar-
ily phenomenological alterations detected by plant lectins 
and monoclonal antibodies; the emerging concept of the 
sugar code now ascribes functional signifi cance to them 
 [3] . Explicitly, carbohydrate epitopes of cellular glycocon-
jugates serve as ligands for endogenous lectins, and this 
interaction is a key regulator of cell adhesion/migration 
and proliferation  [2, 4] . Especially their spatial accessibil-
ity and versatile substitutions confer prominence to   -
galactosides at chain termini in this respect  [3] . A family 
of lectins, fi ttingly termed ‘galectins’,  exclusively devoted 
to read this type of biochemical signal, has developed [2] . 
Cell biological studies pinpointing members of this fam-
ily as effectors have given reason to localize these lectins 
in situ either by neoglycoproteins or galectin-specifi c an-
tibodies  [5–7] . Of note, respective studies have revealed 
that – in addition to carbohydrate-dependent cell surface 
binding which is sensitive to substitutions in the glycan 
chains  [8, 9] – galectins-1 and -3 also execute important 
malignancy-associated functions in the cytoplasm and 
nucleus, e.g. in positioning of oncogenic H-Ras  [10, 11] . 
These fi ndings add to the interest of examining the ex-
pression of these galectins in tumors and they also suggest 
to introduce labeled galectins to monitor binding-site ex-
pression in parallel. Recombinant expression and label-
ing without impairing binding activity are instrumental 
to produce the reagents for this purpose  [12, 13] . In ad-
dition to monitoring galectins we also assessed features 
related to extracellular matrix lectins, i.e. receptors for 
heparin/heparan sulfate and hyaluronic acid. In this ret-
rospective study on tissue sections from 481 patients we 
ask the questions whether and to what extent these attri-
butes of in vitro growth/adhesion modulation correlate 
with TNM parameters and survival. 
 Patients and Methods 
 Four hundred eighty one patients with lung cancer who under-
went potentially curative surgery between January 1, 1990, and 
December 31, 1995, were included into this study. A total of 246 
patients were treated at the thoracic surgical unit of the Tho-
raxklinik in Heidelberg (Germany) and 235 patients at the Depart-
ment of Surgery of the University of Szeged (Hungary).  Table 1 lists 
the statistical data of the patients (sex, histology and tumor stage) 
Heidelberg Szeged Total p
Men 201 189 390 0.72
Women 45 46 91
Age, years 60.1388.85 57.3388.85 58.788.94 0.001
Histological type
Squamous cell carcinoma 112 114 216 0.786
Adenocarcinoma 92 86 178
Large cell carcinoma 34 33 67
Small cell carcinoma 8 12 20
Stage
I/A 29 31 60 0.524
I/B 95 83 178
II/A 4 2 6
II/B 45 46 91
III/A 71 66 137
III/B 2 4 6
IV 0 3 3
Survival
5-year survival, % 41.4 37.5 0.463
Median survival time, months 43 42
Table 1. Patients at the two surgical 
 centers
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which had to be compared to reliably exclude a center-specifi c pa-
tient bias. With the exception of age, signifi cant differences were 
not observed between the parameters of the two cohorts of patients 
and the survival rates at the two centers. The mean duration of the 
follow-up period was 48.9 months (range 1–125 months). 
 Sections, 4–6   m thick, were prepared from the paraffi n-em-
bedded tumor tissue and the histochemical staining protocol fol-
lowed an optimized procedure as reported in detail previously  [12, 
14] . The biotinylated lectins and hyaluronic acid and the antibod-
ies against lectin were prepared in the Department of Physiological 
Chemistry at the Faculty of Veterinary Science of the Maximilian 
Ludwig University. Following routine inhibition of endogenous 
peroxidase activity and saturation of nonspecifi c protein-binding 
sites and biotin-binding sites, the tissue sections were incubated 
with the probes at room temperature for 60 min. Lectin-binding 
capacities of the tumor cells were studied with labeled (biotinylat-
ed) galectin-1 (Gal-1) and galectin-3 (Gal-3) prepared and checked 
for purity, extent of label incorporation and activity as described 
 [15–18] . Hyaluronic-acid-binding capacity was investigated with 
biotinylated hyaluronic acid dissolved in medium which was either 
Ca 2+  free (HA) or contained 8 mmol/l Ca 2+  (HA+ Ca 2+ ) to test Ca 2+ -
independent and Ca 2+ -dependent binding activities  [19] . The fi nal 
dilution of probes was 10   g/ml. Visualization of specifi c binding 
was performed with the avidin-biotin technique (Vector Laborato-
ries, Burlingame, USA) ( fi g. 1 ). In parallel, serial sections were test-
ed with polyclonal antibodies against galectin-1, galectin-3 and the 
heparin-binding lectin (HBL) which had been examined for target 
specifi city by Western blotting and ELISA assays  [12, 20, 21] . The 
fi nal dilution of probes was 10   g/ml as well. Antigen-dependent 
antibody binding was detected using a commercial monoclonal an-
tibody against rabbit immunoglobulin G, with a streptavidin-biotin 
method as the staining system (BioGenex, San Ramon, USA) 
( fi g. 2 ). Routine light-microscopic assessment of the sections was 
performed by the same pathologist. An automated image-analyzing 
system (DIAS, University of Jena, Germany) was routinely applied 
for bias-free classifi cation of cases into negative or positive on the 
basis of staining intensity and number of stained cells as described 
previously  [14, 21] . The results were put into relation with the pT 
and pN status, the histological fi ndings and survival data. The data 
were subjected to the    2  test and an ANOVA. The Kaplan-Meier 
method and Cox regression analysis were used for the respective 
calculations: in the former method, signifi cance was established 
with a log-rank test. The SPSS 11.0 (SPSS Inc., Chicago, Ill., USA) 
program was applied for the statistical data processing. 
 Results 
 Binding of Galectins and Hyaluronic Acid and 
Presence of Lectins: Relation with Tumor Type and 
Features 
 Carbohydrate-dependent binding of these three probes 
could be detected. As an internal specifi city control and 
evidence for disparate ligand selection, the binding pro-
fi les of the two related galectins were found not to be 
identical. The proportions of tumors with galectin-1- and 
galectin-3-binding capacities showed a discrete increase 
of 8% and 3% in relation to progressive lymph node 
 stages, respectively. However, this increase did not reach 
a statistically signifi cant level. A similar tendency could 
be observed for the tumors displaying galectin-1 expres-
sion (N0: 39.6%, N1: 49.1%, N2: 49.6%, p = 0.106), in 
contrast to galectin-3 expression, which was more fre-
quently seen in N0 tumors (74.7%) than in N1 (64.4%) 
 Fig. 1. Lung adenocarcinoma demonstrating intensive galectin-3-
binding capacity. 
 Fig. 2. Lung large cell carcinoma demonstrating intensive galec -
tin-3 expression. 
 Szöke et al.
 
 Oncology 2005;69:167–174 170
or N2 (67.3%) tumors (p = 0.089). The proportion of the 
hyaluronic-acid-binding tumors increased with advanc-
ing lymph node stages (N0: 31.7%, N1: 34.7%, N2: 36.8%), 
but the difference was not statistically signifi cant (p = 
0.623). When the sections were processed in Ca 2+ -con-
taining medium, the proportion of hyaluronic-acid-bind-
ing tumors was about 10–16% lower, and the distribution 
corresponding to the lymph node metastases changed as 
well (N0: 21.5%, N1: 13.5%, N: 20%, p = 0.187). 
 The proportion of tumors expressing galectin-1 in-
creased with advancing T stages (T1: 42.4%, T2: 43.3%, 
T3: 46.1%, p = 0.885). In contrast, the proportion of tu-
mors with galectin-3-binding capacity (T1: 47.9%, T2: 
39% and T3: 36.5%, p = 0.278) and galectin-3 expression 
(T1: 76.7%, T2: 74%, T3: 55%, p = 0.001) decreased to a 
statistically signifi cant extent with increasing pT stage. 
A similar tendency was observed for hyaluronic-acid-
binding capacity (T1: 35.6%, T2: 34%, T3: 30.7%, p = 
0.768 for the Ca 2+ -free medium and T1: 27.4%, T2: 
19.3%, T3: 14.4%, p = 0.1 for Ca 2+ -containing medium, 
respectively). Heparin-binding lectin positivity was found 
to be maximal in pT2 tumors; the number of positive 
cases was about 10% lower in pT1 and pT3 tumors (p = 
0.006). The small number of pT4 (and also pN3) cases 
precluded extension of the calculations. Galectin-1-bind-
ing capacity and galectin-1 expression tended to increase 
with advancing pT and pN stages. In contrast, the num-
ber of galectin-3-positive cases tended to decrease with 
advancing tumor and lymph node stages. 
 The proportion of positive cases was signifi cantly low-
er among the patients with small cell lung cancer for all 
applied probes compared to those of the non-small-cell 
lung cancer group. In four of the cohorts (galectin-1, ga-
lectin-3 and heparin-binding lectin expression and galec-
tin-3-binding capacity) the difference was statistically sig-
nifi cant ( table 2 ). 
 With respect to cell type within the non-small-cell lung 
cancer group, the proportion of positive cases was obvi-
ously higher among the adenocarcinomas than the squa-
mous cell carcinoma or large-cell lung cancer groups with 
the exception of galectin-1 expression. The greatest dif-
ferences were seen for the galectin-3-binding expression 
(about 20%) ( table 2 ). 
 Survival Study 
 Looking at the results of the univariate analysis, the 
5-year survival rate of patients with galectin-3-binding tu-
mors was 33.7%, whereas that of the negative cases was 
42.6%; the median survival  was 35.3 and 45.9 months, 
respectively (p = 0.039) ( fi g. 3 ). The survival of patients 
with galectin-1-expressing tumors was even worse: in case 
of positive staining, the 5-year survival was 32.5%, and the 
median survival time was 35 months, the corresponding 
data for the negative tumors were 44.5% and 48.8 months 
(p = 0.027) ( fi g. 4 ). In the event of Gal-1-binding capacity 
and Gal-3-expression median survival is similarly better 
for the cases with negative-staining tumors, but the differ-
ence between the negative and positive  cases is not sig-
nifi cant. For Gal-1-binding tumors, mean survival is 40 
months, while in the Gal-1-negative cases it is 46 months 
(p = 0.368); for Gal-3-expressing tumors, mean survival is 
42 months, while in the non-staining cases it is 44 months 
(p = 0.255). The survival is better for HBL-expressing tu-
mors (44 months) than for the negative cases (29.2 months), 
but the difference is statistically nonsignifi cant (p = 0.508). 
The HA-binding capacity itself impairs the chances of sur-
vival (33.6 months vs. 44 months), while in the HA + Ca 2+  
medium the survival of cases with HA-binding tumors ex-
ceeds that of the negative cases (51 vs. 40.6 months). The 
difference in survival is not signifi cant. 
 In the multivariate survival calculations, the classical 
prognostic factors (pT, pN and cell type) predicted sur-
Table 2. Distribution (%) of positive cases according to histological type
Cell type n Gal-1 BC Gal-1 EX Gal-3 BC Gal-3 EX HBL EX HA BC HA+Ca2+ BC
Squamous cell carcinoma 216 64.81 38.43 35.19 64.35 73.15 31.94 18.98
Adenocarcinoma 179 73.18 50.84 49.72 83.24 80.45 37.99 21.91
Large cell carcinoma 67 61.19 52.24 34.33 65.67 67.16 28.36 17.91
Small cell carcinoma 18 55.56 15.79 21.05 36.84 26.32 21.05 5.26
p = 0.13 p = 0.003 p = 0.005 p < 0.001 p < 0.001 p = 0.264 p = 0.352
BC = Binding capacity for the biotinylated marker; EX = expression of the lectin.
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 Fig. 3. Cumulative survival of patients with galectin-3 binding and 
nonbinding lung tumors (p = 0.039). 
 Fig. 4. Cumulative survival of patients with galectin-1-expressing 
and nonexpressing lung tumors (p = 0.0274). 
Relative
risk of
deaths
Signifi -
cance
95% CI
Histology <0.003
Squamous cell carcinoma vs. adenocarcinoma 1.277 <0.068 0.981–1.661
Squamous cell carcinoma vs. large cell carcinoma 1.387 <0.061 0.985–1.953
Squamous cell carcinoma vs. small cell carcinoma 2.549 <0.001 1.494–4.346
pT <0.003
pT1 vs. pT2 1.674 <0.004 1.176–2.381
pT1 vs. pT3 2.091 <0.001 1.357–3.224
pN <0.001
pN0 vs. pN1 1.362 <0.031 1.029–1.828
pN0 vs. pN2 2.195 <0.000 1.667–2.961
Galectin-1-binding capacity 1.006 <0.963 0.783–1.292
Galectin-3-binding capacity 0.736 <0.010 0.582–0.928
Galectin-1 expression 0.897 <0.375 0.706–1.140
Galectin-3 expression 0.761 <0.030 0.594–0.974
CL-16-binding capacity 0.941 <0.643 0.727–1.217
Heparin-binding lectin expression 1.158 <0.316 0.869–1.542
Hyaluronic acid binding capacity 0.894 <0.379 0.698–1.147
Hyaluronic acid binding capacity (+Ca2+) 1.268 <0.119 0.940–1.709
Table 3. Multivariate analysis of survival 
of radically operated lung cancer patients 
according to histological type, TNM 
 classifi cation, lectin-binding capacity and 
lectin expression
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vival reliably. From the tested probes, galectin-3-binding 
capacity and galectin-3 expression proved to be an inde-
pendent prognostic factor: negative cases displayed an 
improved survival rate at a statistically signifi cant level 
( table 3 ). In the non-small-cell lung cancer group there 
was no difference in survival between the histological 
types. According to multivariate analysis, the lymph node 
status ranked fi rst followed by the galectin-3-binding ca-
pacity when estimating the prognostic factors (p = 0.011), 
increases in the status of the T classifi cation likewise neg-
atively infl uencing survival ( table 4 ). 
 Discussion 
 Based on our data galectin-related characteristics ap-
pear to be relevant for lung tumor behavior in patient 
material. These studies are essential to relate galectins to 
clinical procedures, because cell lines may confound in-
terpretation owing to unique properties of distinct lines. 
Also, the in vivo data are critical to pinpoint cell-type-
specifi c attributes potentially relevant for design of thera-
peutic approaches. An example of dependence on cell 
type is provided by previous measurements on metastasis 
formation from breast and colon cancer to the lung  [21] . 
Regarding thoracic tumors and relating to the results of 
our study, histological differential diagnosis of epithelial 
mesothelioma reached sensitivity and specifi city in the 
case of the hyaluronic-acid-binding capacity of 87 and 
91%, respectively  [19] . The survival rate for patients 
whose tumor was positive with labeled hyaluronic acid 
was better than that for cases which gave negative results 
on histochemical examination  [19] . The introduction of 
this marker to visualize binding capacity for this glycos-
aminoglycan which participates in growth regulation and 
tissue remodeling to lung carcinoma yielded no prognos-
tic information, in contrast to galectin-dependent param-
eters. 
 The observation that the survival rate of patients with 
galectin-3-binding tumors is signifi cantly poorer than 
that of the negative cases is a salient result of this study. 
Survival likewise decreases, though not at a statistically 
signifi cant level, in the event of galectin-3 expression. Ga-
lectin-3 plays a role in the progression of tumors at sev-
eral points. It promotes the angiogenesis of tumor tissue 
 [22] and can block growth-inhibitory effects of galec-
tins-1 and -7  [16] . Unlike homodimeric galectins, galec-
tin-3 can form pentamers besides the monomer, and is 
thus capable of generating different cross-linked com-
plexes with ligands  [15, 23, 27, 28] . Moreover, it has a 
distinct pattern of intracellular binding. Galectin-3 is a 
well-known anti-apoptotic effector and  enhanced galec-
tin-3 levels are known to inhibit nitrogen-oxide-induced 
apoptosis in BT549 breast tumor cells  [7, 11] . And in-
Relative
risk of
death
Signifi -
cance
95% CI
Histology <0.100
Squamous cell carcinoma vs. adenocarcinoma 1.272 <0.074 0.976–1.655
Squamous cell carcinoma vs. large cell carcinoma 1.376 <0.068 0.976–1.937
pT <0.007
pT1 vs. pT2 1.651 <0.008 1.142–2.387
pT1 vs. pT3 2.047 <0.002 1.302–3.218
pN <0.001
pN0 vs. pN1 1.403 <0.023 1.047–1.878
pN0 vs. pN2 2.137 <0.001 1.590–2.872
Galectin-1-binding capacity 1.009 <0.945 0.779–1.306
Galectin-3-binding capacity 0.734 <0.011 0.578–0.932
Galectin-1-expression 0.852 <0.201 0.667–1.088
Galectin-3-expression 0.783 <0.058 0.607–1.008
CL-16-binding capacity 0.914 <0.508 0.699–1.193
Heparin-binding lectin expression 1.172 <0.291 0.872–1.574
Hyaluronic-acid binding capacity 0.900 <0.417 0.698–1.160
Hyaluronic-acid-binding capacity (+Ca2+) 1.277 <0.113 0.943–1.728
Table 4. Multivariate analysis of survival 
of radically operated non–small cell lung 
cancer patients according to histological 
type, TNM classifi cation, lectin-binding 
capacity and lectin expression
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deed, in a study by Sheikholeslam-Zadeh et al.  [24],  im-
munohistochemical monitoring revealed increased galec-
tin-3 expression in cholesteatomas that counteracted 
apoptosis. The combination of TTF-1 and galectin-3 con-
stitutes an independent prognostic factor indicating that 
galectin-3 may interfere with tumor progression by en-
hancing the transcriptional effect of TTF-1  [25] . With 
most of the examined lectins, the cells of small cell lung 
cancer displayed a considerably lower binding capacity 
and expression than those of non-small-cell lung cancer. 
A similar conclusion was reached by Buttery et al. [26] , 
who investigated the expression of galectin-3 in lung can-
cer. We assume that the different biological behavior of 
small cell carcinoma (rapid spread, early metastatization 
and chemosensitivity) may be connected with these re-
sults. 
 In addition to galectin-3, we also included galectin-1 
monitoring to  clarify the role of this lectin in lung cancer 
as well. Our results indicate that galectin-1 expression by 
tumor cells is associated with a poor survival rate. In the 
event of more advanced pT and pN stages, the proportion 
of positive cases tended to be higher, in contrast with the 
situation for galectin-3. A similar tendency was observed 
in breast carcinoma, where galectin-1 expression occurs 
with a higher frequency in cases expressing lymph node 
metastases than in those without evident lymph node in-
volvement, while colon cancer yielded opposite results, 
emphasizing cell type specifi city  [21] . Galectin-1 indeed 
has a pronounced cell-type-specifi c reactivity profi le. In 
vitro and in vivo measurements including analysis of bi-
opsies showed growth-inhibitory effects on neuroblasto-
ma and T leukemic cells and tumor-promoting effects in 
glioblastoma  [29, 30] . As binding partner of oncogenic 
H-Ras, galectin-1 is an effector of cell transformation 
 [10] . It is an important conclusion of our study that ga-
lectin-related features are of prognostic signifi cance in 
lung cancer. The cell type specifi city of galectin function-
ality precludes immediate predictions. The reported re-
sults and the emerging network of galectins now pose the 
challenge to perform galectin fi ngerprinting in lung can-
cer in order to delineate the interplay between the differ-
ent members of this family  [31] . Explicitly, monitoring of 
the presence of galectin and binding capacity beyond ga-
lectins-1 and -3 will be a promising subject for future in-
vestigations. 
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